Form 4: Vertex Pharma Exec Sells Shares Under 10b5-1 Plan

Vertex Pharmaceuticals' EVP, Chief Regulatory & Quality Officer, Ourania Tatsis, sold 4,500 shares of common stock for approximately $449.99 per share.

Summary

• Ourania Tatsis, EVP, Chief Regulatory & Quality Officer at Vertex Pharmaceuticals Inc. (VRTX), sold 4,500 shares of common stock.
• The transaction occurred on December 3, 2025, at a weighted average price of $449.99 per share, with prices ranging from $449.99 to $450.00.
• The sale was executed under a Rule 10b5-1 trading plan, which was established on August 21, 2025.
• Following this transaction, Dr. Tatsis beneficially owns 46,793 shares of Vertex Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine insider sale executed under a pre-arranged 10b5-1 trading plan, which typically indicates a neutral event rather than a reaction to new material information. The sale itself is a reduction in insider holdings, but the pre-planned nature mitigates negative sentiment.

Future Outlook

No specific future outlook or guidance is provided in this insider transaction report.

Management Comments

• Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025.
• Dr. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Industry Context

This is a routine insider transaction and does not provide specific insights into broader industry trends or competitive landscape beyond the company's stock valuation at the time of sale.

Related Party Transactions

• Ourania Tatsis, an executive officer of Vertex Pharmaceuticals Inc., sold 4,500 shares of the company's common stock.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but executed under a pre-planned 10b5-1 plan, which generally minimizes concerns about management's view of future prospects.

Next Steps

• Dr. Tatsis undertakes to provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer, or a security holder.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-scheduled insider stock sale by an executive officer under a Rule 10b5-1 plan. Such transactions are generally not indicative of a change in the company's fundamental outlook or performance. Therefore, it does not provide new information that would warrant a change in investment recommendation based solely on this filing. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Vertex Pharmaceuticals, VRTX, Insider Trading, Form 4, Stock Sale, Ourania Tatsis, 10b5-1 Plan, Executive Compensation